secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gossamer Bio, Inc. (GOSS)
CIK:        0001728117
Form:       8-K
Filed at:   2024-08-12T23:59:59+00:00
Accession:  0001728117-24-000086
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gossamer Bio Q2 2024 net income $49.2M; cash $354.5M; Chiesi collaboration on track
--------------------------------------------------------------------------------

- Net income $49.2M ($0.22 basic EPS) vs net loss $42.5M in Q2 2023.
- Cash, cash equivalents & marketable securities $354.5M as of June 30, 2024; runway into H1 2027.
- Revenue from Chiesi collaboration: $88.8M license sale + $7.1M R&D services.
- R&D expenses $35.1M (vs $36.3M); G&A expenses $8.7M (vs $10.0M).
- PROSERA Phase 3 PAH trial enrollment ongoing; top-line results expected Q4 2025; Phase 3 PH-ILD trial to start mid-2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728117/000172811724000086/0001728117-24-000086-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728117/000172811724000086/goss-20240812.htm
  HTML page:      https://secwatch.observer/filing/0001728117-24-000086

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer